Health Care Partner Addresses FDA Bid to Lower Drug Prices in The Washington Post

In The News
July 19, 2018
Thomas N. Bulleit
Capital Insights.

Health care partner Tom Bulleit (Washington, D.C.) addressed the U.S. Food & Drug Administration’s bid to lower drug prices in a July 18 article published in The Washington Post that was reprinted in The San Francisco Chronicle and Connecticut Post.

Mr. Bulleit expressed skepticism that policy actions suggested so far by FDA, which has no official role in how drug prices are set, would result in significant decreases in list prices for prescription drugs, or the out-of-pocket costs of any substantial number of health care consumers.


Thomas N. Bulleit
Thomas N. Bulleit
Retired Partner